Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ First patient enrolled in Phase 3 trial evaluating phentolamine ophthalmic solution ➤ FDA clears IND amendment for Phase 3 retinitis pigmentosa gene therapy study ➤ Successful pre-submission meetings held for bioengineered corneal implants ➤ Study: AI chatbots pass ophthalmology board certification questions ➤ ASCRS news and events
➤ Phase 3 results for new corticosteroid ➤ Positive topline results from Phase 3 trials investigating presbyopia drop ➤ Phase 2 data presented for IOP-lowering intracameral implant ➤ First patient dosed in retinitis pigmentosa gene therapy ➤ Survey shows burden of pterygium ➤ ASCRS news and events
➤ One-year data from first-in-human drug eluting IOL ➤ Company begins two Phase 2 studies for glaucoma treatment ➤ First patient dosed in allogenic cell therapy trial ➤ Company outlines resubmission plan for reproxalap NDA ➤ Safety information for the upcoming solar eclipse ➤ Upcoming company presentations at Eyecelerator and the ASCRS Annual Meeting ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Positive topline results in trial for retinitis pigmentosa treatment ➤ Phase 2 trial for first-in-human inflammatory dry eye therapy ➤ Landmark clinical trial shows non-inferiority of Nanodropper technology ➤ Dosing complete for gene therapy aiming to help patients with Leber congenital amaurosis ➤ Enrollment begins for secondary IOL technology Phase 1 pivotal trial ➤ Strategic alignment news ➤ ASCRS news and events
➤ Phase 3 results reported for novel glaucoma eye drop ➤ Update: preventative therapy for patients at risk for radiation retinopathy ➤ Topical drop for diabetic retinopathy does not meet endpoints in Phase 2 trial ➤ ASCRS news and events
➤ Phase 3 clinical trial for water-free dry eye cyclosporine drop ➤ Phase 2b results for drug-eluting contact lens for glaucoma ➤ Dosing continues for Phase 1/2 trial evaluating gene therapy for X-linked retinoschisis ➤ Higher dose, extended wet AMD treatment non-inferior to standard of care ➤ Study: AI detects severe retinopathy of prematurity with 100% accuracy ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ FDA approves new drug for postop inflammation and pain ➤ Primary endpoints in unadjusted population not met in Phase 3 trial for dry eye drop ➤ Study links inherited eye diseases to gut bacteria ➤ Acquisitions and other news ➤ ASCRS news and events
➤ Enrollment complete in Phase 2 study for drug targeting endocannabinoid system for IOP lowering ➤ Dosing complete for Phase 1/2 trial evaluating a gene therapy for Stargardt disease ➤ Pre-Phase 3 Type B meeting held with FDA by company focused on retinitis pigmentosa ➤ Updates from several late-stage clinical trials ➤ New company launches to pioneer nonviral gene therapies ➤ ASCRS news and events
➤ Study: artificial intelligence matches/outperforms ophthalmologists ➤ Primary endpoint met in Phase 3 trial using an antibody to treat thyroid eye disease ➤ FDA grants Breakthrough Device Designation to novel spectacle design ➤ ASCRS news and events
➤ FDA approves IND for neuropathic pain drug ➤ Phase 2 preliminary efficacy and safety data for wet AMD treatment trial ➤ First-in-human data for DME, AMD therapy ➤ Study: Rapid eye stroke detection protocol helps prevent vision loss ➤ Enrollment complete for Phase 3 trial for sozinibercept ➤ ASCRS news and events